Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective.
Orphanet J Rare Dis
; 18(1): 79, 2023 04 11.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2295481
ABSTRACT
BACKGROUND:
Traditional clinical trials require tests and procedures that are administered in centralized clinical research sites, which are beyond the standard of care that patients receive for their rare and chronic diseases. The limited number of rare disease patients scattered around the world makes it particularly challenging to recruit participants and conduct these traditional clinical trials. MAIN BODY Participating in clinical research can be burdensome, especially for children, the elderly, physically and cognitively impaired individuals who require transportation and caregiver assistance, or patients who live in remote locations or cannot afford transportation. In recent years, there is an increasing need to consider Decentralized Clinical Trials (DCT) as a participant-centric approach that uses new technologies and innovative procedures for interaction with participants in the comfort of their home.CONCLUSION:
This paper discusses the planning and conduct of DCTs, which can increase the quality of trials with a specific focus on rare diseases.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Cuidadores
/
Enfermedades Raras
Tipo de estudio:
Estudio pronóstico
/
Ensayo controlado aleatorizado
Límite:
Anciano
/
Niño
/
Humanos
Idioma:
Inglés
Revista:
Orphanet J Rare Dis
Asunto de la revista:
Medicina
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
S13023-023-02693-7
Similares
MEDLINE
...
LILACS
LIS